FY2025 Earnings Estimate for Bruker Issued By Zacks Research

Bruker Co. (NASDAQ:BRKR) – Investment analysts at Zacks Research raised their FY2025 earnings per share (EPS) estimates for Bruker in a research note issued to investors on Tuesday, March 11th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $2.68 per share for the year, up from their previous forecast of $2.67. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%.

BRKR has been the topic of several other reports. The Goldman Sachs Group raised Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price on the stock in a research report on Thursday, December 5th. Barclays cut their price target on Bruker from $69.00 to $65.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. Guggenheim reaffirmed a “buy” rating on shares of Bruker in a research report on Monday, February 24th. UBS Group initiated coverage on Bruker in a research report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 target price on the stock. Finally, Stifel Nicolaus dropped their target price on Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a research report on Friday, February 14th. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Bruker has an average rating of “Moderate Buy” and an average target price of $70.50.

Bruker Stock Performance

Shares of BRKR stock opened at $45.97 on Friday. The business’s fifty day simple moving average is $53.93 and its 200-day simple moving average is $58.57. The company has a market cap of $6.97 billion, a PE ratio of 60.49, a PEG ratio of 2.16 and a beta of 1.18. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15. Bruker has a 12-month low of $44.11 and a 12-month high of $94.86.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Monday, March 17th will be given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date is Monday, March 17th. Bruker’s payout ratio is 26.32%.

Institutional Trading of Bruker

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Gordian Capital Singapore Pte Ltd acquired a new position in shares of Bruker in the fourth quarter worth $234,000. EDENTREE ASSET MANAGEMENT Ltd boosted its stake in Bruker by 11.2% in the fourth quarter. EDENTREE ASSET MANAGEMENT Ltd now owns 158,000 shares of the medical research company’s stock valued at $9,262,000 after acquiring an additional 15,900 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Bruker by 17.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 356,969 shares of the medical research company’s stock valued at $20,926,000 after acquiring an additional 52,214 shares in the last quarter. Voloridge Investment Management LLC raised its holdings in shares of Bruker by 179.6% in the fourth quarter. Voloridge Investment Management LLC now owns 18,906 shares of the medical research company’s stock valued at $1,108,000 after buying an additional 12,145 shares during the last quarter. Finally, Two Sigma Advisers LP raised its holdings in shares of Bruker by 406.1% in the fourth quarter. Two Sigma Advisers LP now owns 140,700 shares of the medical research company’s stock valued at $8,248,000 after buying an additional 112,900 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.